Google
KYNB 株価分析 — Kyntra Bio, Inc. (Healthcare >> Biotechnology)
KYNB に関するよくある質問
KYNBのPER（株価収益率）は？
Kyntra Bio, Inc.（KYNB）は現在PER 0.15倍で取引されています。
KYNBのROE（自己資本利益率）は？
Kyntra Bio, Inc.のROEは-373.52%です。
KYNBの配当利回りは？
Kyntra Bio, Inc.の配当利回りは0.00%です。
KYNBの品質スコア（Quality Score）は？
当社のAIはKYNBの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
KYNBは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
KYNBはどのセクターに属しますか？
Kyntra Bio, Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
KYNB AI Analysis Summary
Our AI summary for KYNB: Kyntra Bio, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.15, ROE of -373.52%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.76
Price
0.03
(0.45%)
Day Change
|
|
|---|
KYNB, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
67% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
5
GREAT
|
| Magic Formula Rank by ROE |
5
GREAT
|
| Magic Formula Rank by ROIC |
4
GREAT
|
| Price | 6.76 |
| PBV / Sector |
-0.89 / 44,219.29
|
| Earning Per Share | 40.60 |
| PE / Sector |
0.15 / 19.28
GREAT
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
0.08 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-04 08:01:46 |
| Symbol | KYNB |
| Name | KYNTRA BIO, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 27.24 / 9,645.64 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 350 Bay Street, San Francisco, CA, United States, 94133
Phone: 415 978 1200
Website: https://www.kyntrabio.com
Sector: Healthcare >> Biotechnology
Description: Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
